Crosscheck

Your medical. Crosschecked.

Neurofibromatosis

What the FAA's documents say about neurofibromatosis, in plain words, with the FAA's own words one press away.

FAA term: Neurofibromatosis (Type 1/NF-1 von Recklinghausen Disease and Type 2/NF-2 Wishart Disease)

FAA source: Neurofibromatosis. FAA date 24 September 2025. Checked by Crosscheck 14 October 2026

Short version

The disposition table has two rows, Type 1 (NF1, von Recklinghausen disease) and Type 2 (NF2, Wishart disease).

How the FAA's table sorts Neurofibromatosis
SituationWhat the examiner doesPathway
Row AType 1 (NF1), von Recklinghausen disease
Defers to the FAA
Special Issuance
Row BType 2 (NF2), Wishart disease
Defers to the FAA
Special Issuance
Show the FAA's words: the FAA's table for Neurofibromatosis
  1. Row A · Special Issuance

    Neurofibromatosis Type 1 (NF1), von Recklinghausen disease. The table lists what to submit for FAA review, and the examiner defers and submits the information to the FAA for a possible Special Issuance.

    A. Neurofibromatosis Type 1 (NF1) von Recklinghausen disease … Submit the following for FAA review: … DEFER Submit the information to the FAA for a possible Special Issuance.

    FAA source: Neurofibromatosis. FAA date 24 September 2025. Checked by Crosscheck 14 October 2026

  2. Row B · Special Issuance

    Neurofibromatosis Type 2 (NF2), Wishart disease. The table lists what to submit for FAA review, and the examiner defers and submits the information to the FAA for a possible Special Issuance.

    B. Neurofibromatosis Type 2 (NF2) Wishart Disease … Submit the following for FAA review: … DEFER Submit the information to the FAA for a possible Special Issuance.

    FAA source: Neurofibromatosis. FAA date 24 September 2025. Checked by Crosscheck 14 October 2026

What the pathway names mean

The FAA pathways for neurofibromatosis

Which exam

Which one describes yours?

The FAA's table sorts it these ways. Choose yours to see its plan.

Your step-by-step plan

  1. Step 1: Neurological evaluation

    From the treating neurologist, for either type.Within 90 days before the exam

    A current, detailed neurological evaluation that meets FAA Specifications for Neurologic Evaluation, from a clinic visit with your treating neurologist, no more than 90 days before the exam.

    After brain surgery

    Brain surgery including resection of benign tumors that requires dural penetration (except resection of vestibular Schwannomas) requires a 2-year recovery period.

    Show the FAA's words: Neurological evaluation

    A current, detailed neurological evaluation that meets FAA Specifications for Neurologic Evaluation, generated from a clinic visit with the treating neurologist no more than 90 days before the AME exam.

    FAA source: Neurofibromatosis. FAA date 24 September 2025; checked by Crosscheck 14 October 2026.

    Note: Brain surgery including resection of benign tumors that requires dural penetration (except resection of vestibular Schwannomas) requires a 2-ye ar recovery period.

    FAA source: Neurofibromatosis. FAA date 24 September 2025; checked by Crosscheck 14 October 2026.

  2. Step 2: Brain MRI

    With and without contrast, no more than 90 days before the exam.Within 90 days before the exam

    A brain MRI with and without contrast, no more than 90 days before the exam, as reports and CD.

    How images are sent

    • The interpretive report on paper
    • The images on CD in DICOM readable format, with a file named 'DICOMDIR' in the root directory of the CD-ROM
    • The CD verified to display the images before sending
    • A copy of all films kept, as a safeguard if lost in the mail
    Show the FAA's words: Brain MRI

    Brain MRI with and without contrast performed no more than 90 days before the AME exam (reports and CD)*.

    FAA source: Neurofibromatosis. FAA date 24 September 2025; checked by Crosscheck 14 October 2026.

    For all images (CT/MRI), submit the interpretive report on paper and imaging on CD in DICOM readable format (there must be a file named 'DICOMDIR' in the root directory of the CD-ROM). Please verify the CD will display the images before sending. Retain a copy of all films as a safeguard if lost in the mail.

    FAA source: Neurofibromatosis. FAA date 24 September 2025; checked by Crosscheck 14 October 2026.

  3. Step 3: Eye evaluation and visual field test

    From the treating ophthalmologist, each within 90 days.Two things to bring
    • Eye evaluation

      Within 90 days before the exam

      An eye evaluation from a board-certified ophthalmologist (NOT optometrist): a current, detailed progress note from a clinic visit no more than 90 days before the exam.

      The note

      • A detailed summary of any eye conditions
      • Current medications, dosage and any side effects
      • Physical exam findings
      • Results of any testing performed
      • Diagnosis
      • Assessment and plan (prognosis)
      • Follow-up
    • Threshold visual field test

      Threshold visual field testing with good reliability (30-2 or 24-2), performed within the previous 90 days, interpreted by your treating ophthalmologist.

    Show the FAA's words: Eye evaluation and visual field test

    Eye evaluation from a board- certified ophthalmologist (NOT optometrist). Submit a current, detailed Clinical Progress Note, generated from a clinic visit with the treating ophthalmologist no more than 90 days before the AME exam. It must include a detailed summary of the any eye conditions; current medications, dosage, and side effects (if any); physical exam findings; results of any testing performed; diagnosis; assessment and plan (prognosis); and follow-up.

    FAA source: Neurofibromatosis. FAA date 24 September 2025; checked by Crosscheck 14 October 2026.

    Eye evaluation from a board-certified ophthalmologist (NOT optometrist). A current, detailed Clinical Progress Note generated from a clinic visit with the treating ophthalmologist no more than 90 days before the AME exam. It must include a detailed summary of the history of any eye conditions; current medications, dosage, and side effects (if any); physical exam findings; results of any testing performed; diagnosis; assessment; plan (prognosis); and follow-up.

    FAA source: Neurofibromatosis. FAA date 24 September 2025; checked by Crosscheck 14 October 2026.

    Threshold Visual field testing with good reliability (30-2 or 24-2) performed within the previous 90 days with an interpretation of the visual field testing by the treating ophthalmologist.

    FAA source: Neurofibromatosis. FAA date 24 September 2025; checked by Crosscheck 14 October 2026.

  4. Step 4: Other imaging and testing

    Anything already done, or that your treating physician finds necessary.Two things to bring
    • Other neuroimaging already performed

      If already performed.

      If already performed.

      Any other neuroimaging, such as MRI of the spine, plexus or optic nerves, the most recent, if already performed, as reports and CD.

    • Other testing

      If your treating physician deems it clinically necessary.

      If your treating physician deems it clinically necessary.

      Any other testing deemed clinically necessary by your treating physician.

    Show the FAA's words: Other imaging and testing

    Any other neuroimaging such as MRI spine, plexus, optic nerves, or other areas, most recent, if already performed (reports and CD)*.

    FAA source: Neurofibromatosis. FAA date 24 September 2025; checked by Crosscheck 14 October 2026.

    Any other testing deemed clinically necessary by the treating physician.

    FAA source: Neurofibromatosis. FAA date 24 September 2025; checked by Crosscheck 14 October 2026.

  5. Step 5: Neuropsychological evaluation

    Required in most cases; the kind depends on your history.

    A neuropsychological (NP) evaluation, required in most cases. The type may vary.

    The table says the applicant may want to wait until FAA review of the other items before obtaining NP testing.

    Which FAA specifications

    A history of cognitive impairment, brain lesion, or brain surgery
    FAA Specifications for Neuropsychological Evaluations for Potential Neurocognitive Impairment
    A history or suspicion of learning disability or ADHD
    FAA Specifications for Neuropsychological Evaluation for ADHD
    No history
    The FAA may accept an abbreviated evaluation after review of the other neurologic evaluation items
    Show the FAA's words: Neuropsychological evaluation

    Neuropsychological (NP) evaluation is required in most cases. The type of evaluation may vary. The applicant may want to wait until FAA review of other items above before obtaining NP testing. • If a history of cognitive impairment, brain lesion, or brain surgery: FAA Specifications for Neuropsychological Evaluations for Potential Neurocognitive Impairment is required; • If there is a history or suspicion of learning disability or ADHD: FAA Specifications for Neuropsychological Evaluation for ADHD is required needed; • If no history: FAA may accept an abbreviated evaluation after review of the other neurologic evaluation items.

    FAA source: Neurofibromatosis. FAA date 24 September 2025; checked by Crosscheck 14 October 2026.

    Neuropsychological (NP) evaluation is required in most cases. The type of evaluation may vary. The applicant may want to wait until FAA review of other items above before obtaining NP testing.

    • If a history of cognitive impairment, brain lesion, or history or brain surgery: FAA Specifications for Neuropsychological Evaluations for Potential Neurocognitive Impairment is required; • If there is a history or suspicion of learning disability or ADHD: FAA Specifications for

    Neuropsychological Evaluation for ADHD is required; • If no history - FAA may accept an abbreviated evaluation after review of the other neurologic evaluation items.

    FAA source: Neurofibromatosis. FAA date 24 September 2025; checked by Crosscheck 14 October 2026.

  6. Step 6: See your AME

    The table lists what to submit for FAA review, and the examiner defers and submits the information to the FAA for a possible Special Issuance.Exam day
    • The table lists what to submit for FAA review, and the examiner defers and submits the information to the FAA for a possible Special Issuance.
    Show the FAA's words: See your AME

    A. Neurofibromatosis Type 1 (NF1) von Recklinghausen disease

    Submit the following for FAA review:

    DEFER Submit the information to the FAA for a possible Special Issuance.

    FAA source: Neurofibromatosis. FAA date 24 September 2025; checked by Crosscheck 14 October 2026.

  7. Step 7: After the FAA decides

    For Type 1, the FAA publishes an AASI. It says an FAA physician provides the initial certification decision and grants the Authorization, and that examiners may then reissue under the Authorization when the pilot provides what it lists.
    • For Type 1, the FAA publishes an AASI. It says an FAA physician provides the initial certification decision and grants the Authorization, and that examiners may then reissue under the Authorization when the pilot provides what it lists.
    Show the FAA's words: After the FAA decides

    AASI for Neurofibromatosis Type 1 (NF1)

    An FAA physician provides the initial certification decision and grants the Authorization in accordance with 14 CFR § 67.401.

    AMEs may re-issue an airman medical certificate under the provisions of an Authorization, if the applicant provides the following:

    FAA source: AASI – Neurofibromatosis Type 1. FAA date 28 January 2026; checked by Crosscheck 14 October 2026.

What the examiner checks

It depends on which row of the FAA's table describes the case.

  • Row ADefers to the FAASpecial Issuance

    The table lists what to submit for FAA review, and the examiner defers and submits the information to the FAA for a possible Special Issuance.

    If the examiner defers
  • Row BDefers to the FAASpecial Issuance

    The table lists what to submit for FAA review, and the examiner defers and submits the information to the FAA for a possible Special Issuance.

    If the examiner defers
Show the FAA's words: what the examiner does on each row
  1. Row A · Special Issuance

    Neurofibromatosis Type 1 (NF1), von Recklinghausen disease. The table lists what to submit for FAA review, and the examiner defers and submits the information to the FAA for a possible Special Issuance.

    A. Neurofibromatosis Type 1 (NF1) von Recklinghausen disease … Submit the following for FAA review: … DEFER Submit the information to the FAA for a possible Special Issuance.

    FAA source: Neurofibromatosis. FAA date 24 September 2025. Checked by Crosscheck 14 October 2026

  2. Row B · Special Issuance

    Neurofibromatosis Type 2 (NF2), Wishart disease. The table lists what to submit for FAA review, and the examiner defers and submits the information to the FAA for a possible Special Issuance.

    B. Neurofibromatosis Type 2 (NF2) Wishart Disease … Submit the following for FAA review: … DEFER Submit the information to the FAA for a possible Special Issuance.

    FAA source: Neurofibromatosis. FAA date 24 September 2025. Checked by Crosscheck 14 October 2026

If the examiner defersSpecial Issuance

The table marks Type 1 (NF1), von Recklinghausen disease, DEFER.

The table marks Type 2 (NF2), Wishart disease, DEFER.

Show the FAA's words: if the examiner defers

When the examiner defers

  1. Reason 1

    The table marks Type 1 (NF1), von Recklinghausen disease, DEFER.

    A. Neurofibromatosis Type 1 (NF1) von Recklinghausen disease … DEFER Submit the information to the FAA for a possible Special Issuance.

    FAA source: Neurofibromatosis. FAA date 24 September 2025. Checked by Crosscheck 14 October 2026

  2. Reason 2

    The table marks Type 2 (NF2), Wishart disease, DEFER.

    B. Neurofibromatosis Type 2 (NF2) Wishart Disease … DEFER Submit the information to the FAA for a possible Special Issuance.

    FAA source: Neurofibromatosis. FAA date 24 September 2025. Checked by Crosscheck 14 October 2026

After the FAA decides

AASI

For Type 1, the FAA publishes an AASI. It says an FAA physician provides the initial certification decision and grants the Authorization, and that examiners may then reissue under the Authorization when the pilot provides what it lists.

Show the FAA's words: after the FAA decides
AASI for Neurofibromatosis Type 1 (NF1) … An FAA physician provides the initial certification decision and grants the Authorization in accordance with 14 CFR § 67.401. … AMEs may re-issue an airman medical certificate under the provisions of an Authorization, if the applicant provides the following:

FAA source: AASI – Neurofibromatosis Type 1. FAA date 28 January 2026. Checked by Crosscheck 14 October 2026

What a Special Issuance is

The Guide says an Authorization for Special Issuance, valid for a specified period, may be granted at the Federal Air Surgeon's discretion to a person who does not meet the established medical standards, if the person shows to the satisfaction of the Federal Air Surgeon that the duties authorized by the class of certificate applied for can be performed without endangering public safety during the period the Authorization would be in force.

How the FAA pathways work

Good to know

Points from the FAA's own documents that are easy to miss.

  • What a progress note must include

    In most cases it should come from a visit with the treating physician no more than 90 days ago, and cover the history, medications with dosages and side effects, exam findings, test results, diagnosis, assessment and plan, prognosis and follow-up. The FAA's sheet says to make sure the physician adds the prognosis. A portal note or an After Visit Summary that does not meet these criteria is not enough, and neither is a simple "ok to fly" letter. The FAA's documents also call it a status report.

    Show the FAA's words: good to know, 1
    your patient portal to print out “notes” or an “After Visit Summary (AVS).” … Patient Portal notes or an AVS that do not meet the criteria listed below for a detailed Clinical Progress Note are NOT sufficient for FAA purposes. … To be “current,” in MOST CASES, the detailed Clinical Progress Note should be from an evaluation in which you saw your treating physician no more than 90 days ago. … It Must include the following items: … A summary of the history of the condition, … Current medications, dosages, and side effects (if any); … Clinical exam findings; … Results of any testing performed; … Diagnosis; … Assessment and Plan; … Prognosis (This item may not be on a standard progress note, make sure your physician adds this information.); and … Follow-up … Please note: A letter stating, “Mr. Smith is ok to fly” (or any other simple note), is NOT a current, detailed Clinical Progress Note and is NOT acceptable. … You may also see this called a “current status report” or “status report” in current FAA Guidance. Any reference to a “status report” equals the criteria listed on this sheet.

    FAA source: Pilot Information – What a Detailed Clinical Progress Note must contain. FAA date 25 September 2024. Checked by Crosscheck 14 October 2026

  • The eye evaluation is an ophthalmologist's

    For both types the table asks for the eye evaluation from a board-certified ophthalmologist, NOT an optometrist, from a clinic visit no more than 90 days before the exam.

    Show the FAA's words: good to know, 2
    Eye evaluation from a board-certified ophthalmologist (NOT optometrist). A current, detailed Clinical Progress Note generated from a clinic visit with the treating ophthalmologist no more than 90 days before the AME exam.

    FAA source: Neurofibromatosis. FAA date 24 September 2025. Checked by Crosscheck 14 October 2026

    Eye evaluation from a board- certified ophthalmologist (NOT optometrist). Submit a current, detailed Clinical Progress Note, generated from a clinic visit with the treating ophthalmologist no more than 90 days before the AME exam.

    FAA source: Neurofibromatosis. FAA date 24 September 2025. Checked by Crosscheck 14 October 2026

  • Neuropsychological testing may wait

    The table says a neuropsychological evaluation is required in most cases, and that the applicant may want to wait until FAA review of the other items before obtaining NP testing.

    Show the FAA's words: good to know, 3
    Neuropsychological (NP) evaluation is required in most cases. The type of evaluation may vary. The applicant may want to wait until FAA review of other items above before obtaining NP testing.

    FAA source: Neurofibromatosis. FAA date 24 September 2025. Checked by Crosscheck 14 October 2026

  • Brain surgery has a 2-year recovery period

    The table's note says brain surgery including resection of benign tumors that requires dural penetration, except resection of vestibular Schwannomas, requires a 2-year recovery period.

    Show the FAA's words: good to know, 4
    Note: Brain surgery including resection of benign tumors that requires dural penetration (except resection of vestibular Schwannomas) requires a 2-ye ar recovery period.

    FAA source: Neurofibromatosis. FAA date 24 September 2025. Checked by Crosscheck 14 October 2026

  • Two FAA copies of the Type 1 AASI differ

    The table's PDF prints a copy of the AASI for Type 1 on its last page, updated 09/24/2025. Besides the Authorization and the neurologist's annual progress note, it lists as item 3 an eye evaluation from a board-certified ophthalmologist (NOT optometrist), a current, detailed progress note from a clinic visit no more than 90 days before the exam, which must include interpretation of threshold visual field testing performed within the previous 90 days, and it says the pilot or AME must submit a copy of the above evaluations to the FAA (for both issued or deferred). The AASI sheet published on its own, updated 01/28/2026, lists only the Authorization and the neurologist's annual progress note. This page's reissue list follows the sheet published on its own; both are quoted as published.

    Show the FAA's words: good to know, 5
    AASI for Neurofibromatosis Type 1 (NF1) (Updated 09/24/2025) … 3. Eye evaluation from a board-certified ophthalmologist (NOT optometrist). A current, detailed Clinical Progress Note generated from a clinic visit with the treating ophthalmologist no more than 90 days before the AME exam. … It must include interpretation of Threshold Visual field testing with good reliability (30-2 or 24-2) performed within the previous 90 days by the treating ophthalmologist. … The pilot or AME must submit a copy of the above evaluations to the FAA (for both issued or deferred).

    FAA source: Neurofibromatosis. FAA date 24 September 2025. Checked by Crosscheck 14 October 2026

    AASI for Neurofibromatosis Type 1 (NF1) (Updated 01/28/2026) … 1. An Authorization granted by the FAA; and 2. Annual current, detailed Clinical Progress Note generated from a clinic visit with the treating neurologist no more than 90 days before the AME exam.

    FAA source: AASI – Neurofibromatosis Type 1. FAA date 28 January 2026. Checked by Crosscheck 14 October 2026

  • The AASI is for Type 1

    The FAA's AASI sheet is headed Neurofibromatosis Type 1 (NF1). For a first-time application for it, the examiner must defer and submit all of the documentation to the AMCD or RFS for the initial determination.

    Show the FAA's words: good to know, 6
    AASI for Neurofibromatosis Type 1 (NF1) … If this is first-time application for an AASI for the above disease/condition, and the applicant has all the requisite medical information necessary for a determination, the AME must defer and submit all of the documentation to the AMCD or RFS for the initial determination.

    FAA source: AASI – Neurofibromatosis Type 1. FAA date 28 January 2026. Checked by Crosscheck 14 October 2026

FAA sources

Every FAA document this page relies on, with the FAA's own date and the date Crosscheck last read it. The documents to print open at the FAA, so they are always the FAA's current ones.

This reports what the FAA has published. It is not medical advice, and it does not say how the FAA or an examiner will decide a case.